| Market Cap | 63.85M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -9.02M | Forward P/E | -12.71 | EPS next Y | - | 50D Avg Chg | -4.00% |
| Sales | 103k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -24.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -51.00% |
| Recommedations | - | Quick Ratio | 0.45 | Shares Outstanding | 14.32M | 52W Low Chg | 22.00% |
| Insider Own | 52.58% | ROA | -224.12% | Shares Float | 6.42M | Beta | -1.52 |
| Inst Own | - | ROE | -678.94% | Shares Shorted/Prior | 121.66K/201.81K | Price | 4.45 |
| Gross Margin | 76.70% | Profit Margin | - | Avg. Volume | 1,018 | Target Price | - |
| Oper. Margin | -2,893.65% | Earnings Date | May 10 | Volume | 500 | Change | 0.00% |
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and reconstruction of the colon and uterus wound repair. Its lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. The company also sells Longevity products that focuses on personal healthcare, including longevity dietary supplements. Harvard Apparatus Regenerative Technology Inc. was formerly known as Biostage, Inc. and changed its name to Harvard Apparatus Regenerative Technology Inc. in July 2023. The company was founded in 2009 and is headquartered in Holliston, Massachusetts.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| He Junli | CEO CEO | Dec 27 | Buy | 4.76 | 2,700 | 12,852 | 253,000 | 01/03/24 |
| He Junli | CEO CEO | Dec 14 | Buy | 4.92 | 900 | 4,428 | 250,300 | 12/18/23 |
| He Junli | CEO CEO | Sep 11 | Buy | 5.43 | 1,500 | 8,145 | 247,900 | 09/18/23 |
| He Junli | CEO CEO | Aug 28 | Buy | 4.69 | 3,400 | 15,946 | 246,400 | 09/05/23 |
| He Junli | CEO CEO | Aug 18 | Buy | 4.32 | 8,000 | 34,560 | 243,000 | 08/28/23 |
| Shmerling James E. | Director Director | Aug 21 | Buy | 4.35 | 6,864 | 29,858 | 23,756 | 08/23/23 |
| DST Capital LLC | 10% Owner 10% Owner | Apr 06 | Buy | 6.00 | 62,500 | 375,000 | 3,725,825 | 04/10/23 |
| DST Capital LLC | Director Director | Dec 07 | Sell | 7.17 | 1,952 | 13,996 | 3,663,325 | 12/09/22 |
| Yu Hong | PRESIDENT PRESIDENT | Dec 07 | Sell | 7.17 | 83,676 | 599,957 | 222,459 | 12/09/22 |
| Shmerling James E. | Director Director | May 12 | Buy | 5.92 | 16,892 | 100,001 | 16,892 | 05/23/22 |
| GREEN DAVID | Interim CEO Interim CEO | May 12 | Buy | 5.92 | 63,345 | 375,002 | 158,861 | 05/23/22 |
| DST Capital LLC | 10% Owner 10% Owner | May 12 | Buy | 5.92 | 8,277 | 49,000 | 3,658,277 | 05/19/22 |